IMU-838 tablets + Placebo matching IMU-838 tablets

Phase 3Active
0 watching 0 views this week๐Ÿ“ˆ Rising
69
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Multiple Sclerosis

Conditions

Multiple Sclerosis

Trial Timeline

Nov 18, 2021 โ†’ Sep 1, 2033

About IMU-838 tablets + Placebo matching IMU-838 tablets

IMU-838 tablets + Placebo matching IMU-838 tablets is a phase 3 stage product being developed by Immunic for Multiple Sclerosis. The current trial status is active. This product is registered under clinical trial identifier NCT05134441. Target conditions include Multiple Sclerosis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT05201638Phase 3Active
NCT05134441Phase 3Active